Skip to main content
Premium Trial:

Request an Annual Quote

Centogene CentoXome Gold, CentoXome Platinum

Centogene has released two clinical exome sequencing patient-parent trio tests, CentoXome Gold and CentoXome Platinum. The tests include Sanger confirmation and a medical report, using the company's proprietary CentoMD variant database, and promise reportable variants in more than 60 percent of cases. CentoXome Gold, which covers 95 percent of targets with greater than 10-fold coverage, has a turnaround time of 45 to 60 days and a price of €1,980 ($2,180). CentoXome Platinum covers 95 percent of targets with greater than 20-fold coverage. The test, which is aimed at urgent cases, including prenatal testing, has a turnaround time of less than 15 days and a price of €3,975.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.